Research Topic: Medicinal

Psychotomimetic compensation versus sensitization

This paper proposes a new way to understand why drugs that can cause psychosis-like effects (such as psilocybin, LSD, and ketamine) can also help treat depression and anxiety. The authors suggest that these drugs trigger compensatory responses in the brain that temporarily help us cope with stress, similar to how a runner’s high feels good during exercise. However, if someone uses these drugs repeatedly or experiences chronic stress, they may become sensitized and more vulnerable to developing actual psychotic symptoms over time.

Read More »

Serotonin 5-HT2A receptor expression is chronically decreased in the anterior cerebral cortex of male rats following repetitive low-level blast exposure

Military Veterans exposed to blast explosions often develop long-term problems with memory, anxiety, and PTSD. Researchers found that in rats exposed to blast, a brain receptor called 5-HT2A becomes less active, particularly in the front part of the brain involved in thinking and emotions. This decrease in the receptor correlates with anxiety-like behaviors in the animals. Since psychedelic substances like psilocybin activate this same receptor, the findings suggest that such substances might help treat PTSD and cognitive problems in blast-injured Veterans.

Read More »

Rediscovering Psilocybin as an Antidepressive Treatment Strategy

Scientists have renewed their investigation into psilocybin, a compound found in certain mushrooms, as a potential treatment for depression. Studies show promising results with patients experiencing significant improvements in depressive symptoms, sometimes sustained for months after a single treatment session. When administered in controlled therapeutic environments with professional support, psilocybin appears relatively safe, though it can cause temporary side effects like headaches and anxiety. This research represents an important shift in how we might treat severe depression, especially in patients who haven’t responded to conventional antidepressants.

Read More »

Baicalein as a potent antifungal agent against Candida albicans: synergy with fluconazole and sustainable production through probiotic-mediated bioconversion

Baicalein, a natural compound from a traditional medicinal plant, is significantly more effective at fighting Candida albicans infections than its parent compound baicalin. When combined with the common antifungal drug fluconazole, baicalein creates a powerful synergistic effect that is especially useful against drug-resistant fungal strains. Scientists discovered that a beneficial probiotic bacterium, Lactobacillus rhamnosus, can efficiently convert the abundant baicalin into baicalein, providing a sustainable and safe way to produce this potent antifungal compound at scale.

Read More »

Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study

This study explored how patients with severe depression that didn’t respond to typical treatments experienced psilocybin therapy. Researchers interviewed 11 patients about their experiences and found that building trust with therapists, managing expectations, and having multiple treatment sessions were crucial. Many patients found the experience intense and overwhelming, and most wanted ongoing support to understand what they experienced and how it affected their recovery.

Read More »

Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls

This study followed nearly 1000 people who microdose psilocybin (small regular doses of psilocybin mushrooms) and compared them to 180 people who don’t microdose over one month. Microdosers showed greater improvements in mood, depression, anxiety, and stress compared to the control group. Interestingly, when older adults combined psilocybin with lion’s mane mushrooms and niacin, they showed better improvements in motor control and speed. The effects were fairly consistent across different ages and genders, suggesting psilocybin microdosing may have real benefits for mental health.

Read More »

Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial

This study examined how psilocybin mushroom therapy works for treating depression when combined with talk therapy. Participants received a placebo pill followed by psilocybin four weeks later, both times as part of psychological treatment. The research found that people who received psilocybin showed greater improvements in their ability to accept difficult thoughts and emotions and live according to their values, and these improvements were linked to feeling less depressed.

Read More »

Psychedelics: Safety and Efficacy

This paper reviews scientific research on psychedelic drugs like LSD and psilocybin that are being studied for treating depression and PTSD. While some research claims these drugs are beneficial, many studies have serious flaws including hiding negative side effects and being influenced by money from pharmaceutical companies. The author concludes that we need much better research before these drugs can be safely approved for medical use.

Read More »

Algal pigments: Therapeutic potential and food applications

Colorful algae contain powerful natural compounds that can help treat serious health problems like cancer, diabetes, and obesity. Scientists are using special nano-technology to deliver these algal compounds more effectively in medicines. Algae-based pigments like chlorophyll and carotenoids are already used in supplements and healthy foods to boost overall wellness. These compounds also help maintain a healthy gut and reduce inflammation in the body.

Read More »
Scroll to Top